Lucké 1 has determined the survival time in 100 fatal cases of lower-nephron nephrosis. Ninety-five per cent of the patients succumbed within fourteen days, 86 per cent within ten days ...

They found a significant increase in prescribing rates for both drug classes, with higher prescriptions for GLP-1RAs in patients with obesity and for SGLT2i in patients with cardiovascular and ...

Increases in prescriptions for both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors were observed in patients with type 1 diabetes (T1D ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone in patients with diabetes and established ...

Share on Pinterest More evidence suggests that semaglutide drugs could help lower the risk of Alzheimer’s disease. Image credit: Scharvik/Getty Images. Past research shows that people with type ...

SGLT2i therapy was significantly associated with lower mortality but the association was no longer statistically significant when potential immortal time bias was considered. Treatment with ...

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have cardio-renal protection benefits regardless of diabetes status. However, the outcomes of uninterrupted SGLT2i use peri-percutaneous ...

Researchers conducted a retrospective study to examine the link between sodium glucose co-transporter 2 inhibitors (SGLT2i) use and glaucoma risk in patients with type 2 diabetes mellitus. They ...

Background: Therapeutic options for HFpEF are continuously evolving. The latest AHA guidelines recommend ARNI with a class 2B and SGLT2i with a class 2A for HFpEF. Trials indicate that both SGLT2i and ...

A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to a lower risk of glaucoma. Pleiotropic cardiovascular benefits of sodium ...

Given the extension of the indication for use of SGLT2I to Heart Failure with preserved ejection fraction (HFpEF), in hospital initiation of therapy should also apply to this patient cohort. Purpose ...